Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Dennis C Marshall"'
Autor:
David N. Dahdal, Neal D. Shore, Jehonathan H. Pinthus, Marc B. Garnick, Ferenc G. Rick, Thomas E. Keane, Thomas J.R. Beveridge, Andrew V. Schally, Norman L. Block, Robert H. Eckel, Dennis C Marshall, E. David Crawford
Publikováno v:
Urologic Oncology: Seminars and Original Investigations.
Purpose To explore how follicle-stimulating hormone (FSH) may contribute to cardiovascular, metabolic, skeletal, and cognitive events in men treated for prostate cancer, with various forms of androgen deprivation therapy (ADT). Materials and methods
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 13:251-259
Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels. The authors present an overview of the existing cost-effectiveness studies of ADT in
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 13:261-270
Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate canc
Publikováno v:
Clinical and Experimental Gastroenterology
Gerald Bertiger,1 Edward Jones,2 David N Dahdal,3 Dennis C Marshall,3 Raymond E Joseph3 1Hillmont GI, Flourtown, PA, USA; 2Delaware Valley Nephrology and Hypertension Associates, Philadelphia, PA, USA; 3Ferring Pharmaceuticals Inc., Parsippany, NJ, U
Publikováno v:
Fertility and Sterility. 83:804-807
This study compared the cost and effectiveness of highly purified, human-derived follicle-stimulating hormone (FSH) (Bravelle) to recombinant FSH (Follistim) using Markov modeling and Monte Carlo simulation. One IVF treatment cycle resulted in costs
Publikováno v:
Fertility and Sterility. 77:1202-1208
Objective: To compare the efficacy and safety of Bravelle s.c., Bravelle i.m., and Follistim s.c. in patients undergoing controlled ovarian hyperstimulation for IVF-ET. Design: Open-label, randomized, parallel group, multicenter study. Setting: Eleve
Publikováno v:
American Journal of Gastroenterology. 109:S550-S551
Publikováno v:
Reproductive Biology and Endocrinology, Vol 3, Iss 1, p 61 (2005)
Reproductive biology and endocrinology : RB&E
Reproductive biology and endocrinology : RB&E
Background The use of mixed or blended protocols, that utilize both FSH and hMG, for controlled ovarian hyperstimulation is increasing in use. To reduce the number of injections a patient must administer, many physicians instruct their patients to mi
Autor:
William R. Keye, Mark Surrey, Richard P. Marrs, Jerome H. Check, Vicki L. Schnell, Dennis C Marshall
Publikováno v:
Fertility and sterility. 82(2)
Objective To compare the efficacy and safety of three different ratios of human-derived follicle-stimulating hormone/human menopausal gonadotropin (human-derived FSH:hMG, Bravelle and Repronex) mixed together in the same syringe and administered subc